Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Michael Brawer, MD
Advertisement
Articles by Michael Brawer, MD
Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the significance of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.
Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.
Advertisement
Latest Updated Articles
Dr. Brawer on the Prolaris Genetic Test in Predicting Prostate Cancer AggressivenessPublished: May 22nd 2017 | Updated:
Dr. Brawer on the Significance of the Prolaris Genetic Test for ProstatePublished: August 17th 2017 | Updated:
Dr. Brawer on the Results of the Prolaris Test for Patients Prostate CancerPublished: September 6th 2017 | Updated:
Dr. Brawer on Predicting Radical Prostatectomy OutcomesPublished: July 22nd 2014 | Updated:
Dr. Brawer on Clinical Utility of CCP Test in Prostate CancerPublished: May 17th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5